Alnylam PharmaceuticalsALNY

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Turns RNA interference into drugs, mostly for rare and cardiovascular disease.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$30.4B

Price

$236.01

Today

−0.1%

Return YTD

−40.6%

Return 1Y

−49.5%

P/E

37.6

P/S

6.3

P/B

22.4

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

RNAi medicineRNAi therapyRare diseasesCardiovascular

In the value chain

Products & services

RNAi therapies (amyloidosis)
Cardiovascular RNAi
Research platform

Competitors

Ionis Pharmaceuticals
Pfizer
BridgeBio

Risks

Pipeline concentration
Competition in rare diseases

Supply chain

Supplies →

CencoraCOR

← Suppliers

Charles River LaboratoriesCRL

Full supply chain for ALNY →

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN BiogenBIIB ModernaMRNA IncyteINCY United TherapeuticsUTHR

Compare ALNY

ALNY vs AMGN ALNY vs GILD ALNY vs VRTX ALNY vs REGN ALNY vs BIIB ALNY vs MRNA

See where Alnylam Pharmaceuticals sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →